Interchangeability of Different COVID-19 Vaccine Platforms As Booster Doses: A Phase 3 Study Mimicking Real-world Practice

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2024 May 18

PMID 38762360

Authors

Sue Ann Costa Clemens

Lily Weckx

Eveline P Milan

Igor Smolenov

Ralf Clemens

Affiliations

Soon will be listed here.

Abstract

Background: The COVID-19 pandemic is over but the highly immunized or naturally exposed global population still requires booster vaccinations against newly emerging SARS-CoV-2 variants. We assessed safety and immunogenicity of booster doses of COVID-19 vaccines based on three different platforms in a setting that mimics the current routine practice in Brazil.

Methods: In this phase 3 study from 14 February 2023 to 12 June 2023 we enrolled previously immunized adults to receive an additional booster dose of one of three vaccines. Immunogenicity against ancestor SARS-CoV-2 and Omicron BF.7, BQ.1.1.3, and XBB.1.5.6 sub-lineages was measured as ELISA IgG or virus neutralizing (VNT) antibodies and safety/reactogenicity assessed using diary cards.

Results: Volunteers with a history of full primary COVID-19 immunization striated to three cohorts according to their previous booster vaccination history-0 (n = 26), 1 (n = 140) or 2 (n = 606) booster vaccinations-were randomized 2:1:1 to receive either recombinant protein (SCB-2019, Clover), adenovirus-vector (ChAdOx1-S, AstraZeneca/Fiocruz), or mRNA (BNT162b2, Pfizer/Wyeth). Baseline antibody titers were higher in individuals who had received one or two boosters and titers against both ancestor and Omicron sub-lineages increased in all groups regardless of the number of previous booster doses or the vaccine used. Day 28 geometric mean titers (GMTs) and geometric mean-fold rises (GMFR) against all variants were higher after BNT162b than SCB-2019 or ChAdOx1-S, but BNT162b groups displayed more rapid antibody waning at Day 84. Within cohorts each vaccine elicited similar GMFR against the different SARS-CoV-2 strains. All vaccines were well tolerated with similar solicited reactogenicity profiles.

Conclusions: Protein, adenovirus-vector or mRNA vaccine boosters were equally well tolerated and immunogenic against ancestor SARS-CoV-2 and Omicron sub-lineages in fully primed adults with 0-2 prior boosters. BNT162b induced the highest immune responses but also the most rapid waning of antibodies 3 months after vaccination.

Clinical Trial Registration: ClinicalTrials.gov, identifier NCT05812586.

References

Grana C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H . Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022; 12:CD015477. PMC: 9726273. DOI: 10.1002/14651858.CD015477. View

Ambrosino D, Han H, Hu B, Liang J, Clemens R, Johnson M . Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines. J Infect Dis. 2021; 225(2):327-331. PMC: 8763959. DOI: 10.1093/infdis/jiab574. View

Roa Jr C, de Los Reyes M, Plennevaux E, Smolenov I, Hu B, Gao F . Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults. J Infect Dis. 2023; 228(9):1253-1262. PMC: 10629704. DOI: 10.1093/infdis/jiad262. View

Levin E, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S . Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021; 385(24):e84. PMC: 8522797. DOI: 10.1056/NEJMoa2114583. View

Wong H, Hu M, Zhou C, Lloyd P, Amend K, Beachler D . Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. 2022; 399(10342):2191-2199. PMC: 9183215. DOI: 10.1016/S0140-6736(22)00791-7. View

Bravo L, Smolenov I, Han H, Li P, Hosain R, Rockhold F . Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2022; 399(10323):461-472. PMC: 8776284. DOI: 10.1016/S0140-6736(22)00055-1. View

Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan R . Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022; 40(40):5798-5805. PMC: 9428332. DOI: 10.1016/j.vaccine.2022.08.036. View

Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A . Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021; 10:100208. PMC: 8418937. DOI: 10.1016/j.lanepe.2021.100208. View

Hosain R, Aquino P, Baccarini C, Smolenov I, Li P, Qin H . Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study. Vaccine. 2023; 41(13):2253-2260. PMC: 9915113. DOI: 10.1016/j.vaccine.2023.02.018. View

10.

Menegale F, Manica M, Zardini A, Guzzetta G, Marziano V, dAndrea V . Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023; 6(5):e2310650. PMC: 10157431. DOI: 10.1001/jamanetworkopen.2023.10650. View

11.

Andersson N, Thiesson E, Baum U, Pihlstrom N, Starrfelt J, Faksova K . Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses. BMJ. 2023; 382:e074325. PMC: 10360027. DOI: 10.1136/bmj-2022-074325. View

12.

Wang Q, Guo Y, Bowen A, Mellis I, Valdez R, Gherasim C . XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024; 32(3):315-321.e3. PMC: 10948033. DOI: 10.1016/j.chom.2024.01.014. View

13.

Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D . Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine. 2021; 40(2):306-315. PMC: 8673730. DOI: 10.1016/j.vaccine.2021.12.006. View

14.

Link-Gelles R, Levy M, Natarajan K, Reese S, Naleway A, Grannis S . Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023; 6(3):e232598. PMC: 10018321. DOI: 10.1001/jamanetworkopen.2023.2598. View

15.

Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I . Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021; 397(10275):682-694. PMC: 7906655. DOI: 10.1016/S0140-6736(21)00241-5. View

16.

Clemens S, Pipolo Milan E, Sprinz E, Cerbino Neto J, Pacciarini F, Li P . Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study. Open Forum Infect Dis. 2022; 9(8):ofac418. PMC: 9384758. DOI: 10.1093/ofid/ofac418. View